RxDoctor Payments DataLook up a doctor →

Elaine Zobrist, NP

Adult Health · Fenton, MONPI 1104368018

Payments from drug & device makers

$38,483in general payments, 2019–2025

Across 769 payments — averaging $50.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$25K
  • AstraZeneca$3K
  • UCB, Inc.$2K
  • Amgen$2K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • plus $4K from 21 others

What the payments were for

  • Consulting fees$1,2503%
  • Speaking & faculty fees$19,82552%
  • Travel & lodging$1,6454%
  • Food & beverage$15,55940%
  • Education$2041%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,483 in reported general payments places this provider in the 95th percentile of 555 adult health providers in Missouri.

See all adult health providers in Missouri

Medicare billing

Part B allowed, 2024
$54,451
Medicare patients
285
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab21$323,215
Enbrel SureclickEtanercept28$269,847
EnbrelEtanercept27$214,404
RinvoqUpadacitinib19$124,574
Xeljanz XrTofacitinib Citrate13$75,202
Hydroxychloroquine Sulfate306$9,732
MethotrexateMethotrexate Sodium219$5,470
Leflunomide101$4,912
Mycophenolate Mofetil25$2,265
Celecoxib55$1,979
Sulfasalazine55$1,550
Duloxetine Hcl50$1,440
Folic Acid94$1,105
Azathioprine13$913
Prednisone100$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$1,805$214,40427 claims
AbbVieRinvoq$25,388$124,57419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 555 adult health providers in Missouri.

Other adult health in Fenton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →